PMID: 11514134Aug 22, 2001Paper

The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

European Psychiatry : the Journal of the Association of European Psychiatrists
J LynchJ S Hellewell


This retrospective, case series audit assessed the clinical and health-economic impact of long-term treatment with quetiapine ('Seroquel'), a new atypical antipsychotic, in patients with chronic schizophrenia. The study design was of a case series format, comprising patients entered from one centre into the open-label extension of a multicentre 6-week efficacy study. Twenty-one patients (15 male, six female; mean age 39 years) were studied, of whom 17 (81%) had been rated as 'partially responsive' to previous antipsychotics. Data on hospitalisations and information on symptoms were collected retrospectively for the 12 months before quetiapine treatment was initiated and for the 12 months after. Quetiapine was effective in reducing psychotic symptoms with mean BPRS scores reducing significantly, from 38 to 21 (P < 0.005). Motor function was also significantly improved with mean Simpson scale scores reducing from 15 to 12 (P < 0.005). Average inpatient days were reduced by 11% in year two (97 compared with 109 days) while the overall costs of treatment, including drug costs, fell by 5% (I pound sterling 20,843 to I pound sterling 19,827). Four patients had been hospitalised for longer than 5 years before starting quetiapine; thes...Continue Reading


Jul 1, 1974·Archives of General Psychiatry·T Van Putten
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1995·Schizophrenia Bulletin·S M Evers, A J Ament
Nov 1, 1993·The American Journal of Psychiatry·H Y MeltzerB Snitz
Jan 1, 1997·Clinical Therapeutics·N A Keks
Sep 1, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·G VialeB J Lawrence
Aug 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·K J Aitchison, R W Kerwin
Nov 14, 1997·Acta Psychiatrica Scandinavica·J Peuskens, C G Link
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·M Knapp
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R W Kerwin, K J Aitchison
May 7, 1997·PharmacoEconomics·F RouillonP Auquier
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Kasper, F Müller-Spahn
Apr 20, 2002·The Journal of Mental Health Policy and Economics·M. F. DrummondP. Shadwell
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·J S HellewellA G Awad

❮ Previous
Next ❯


Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
Oct 8, 2014·Irish Journal of Medical Science·C WalshE M M Quigley
Nov 20, 2014·Human Psychopharmacology·Yoshinori WatanabeTenpei Ohtsubo
Jan 9, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Linda M DaviesUNKNOWN CUTLASS Team
Aug 26, 2014·Nutrition Research·Yoon Young ChoiTakayuki Shibamoto
Nov 9, 2002·Hospital Medicine·Jonathan S E Hellewell
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
Mar 20, 2008·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Dimitrios Rovithis, Lycurgus Liaropoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here